Robotic-assisted lobectomy for malignant lung tumors

Area of Science:

• Thoracic Surgery
• Surgical Oncology
• Minimally Invasive Surgery

Background:

• Surgical resection is the primary curative treatment for lung cancer.
• Robotic lobectomy offers a minimally invasive approach to pulmonary malignancy.
• Assessing institutional outcomes of robotic lobectomy is crucial for evaluating its efficacy.

Purpose of the Study:

• To evaluate the institutional outcomes of robotic lobectomy for lung cancer.
• To compare these outcomes with national averages.
• To determine the safety, feasibility, and oncological adequacy of the procedure.

Main Methods:

• Retrospective review of 166 patients undergoing robotic pulmonary lobectomy for malignancy in 2018.
• Data collection included patient demographics, tumor characteristics, operative details, and outcomes.
• Statistical comparison with national averages for key metrics.

Main Results:

• The mean patient age was 75 years, with 73% being current or former smokers.
• The mean tumor size was 2.7 cm, with 11 lymph nodes harvested.
• The conversion rate to open thoracotomy was 7%, with a mean hospital length of stay of 3 days and 0.6% 30-day operative mortality.

Conclusions:

• Robotic lobectomy is a safe, feasible, and oncologically sound procedure for lung cancer.
• Institutional outcomes are comparable to national averages in terms of length of stay, lymph node harvest, conversion rates, and mortality.
• Further research into robotic lobectomies is warranted.